GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Anadys Pharmaceuticals, Inc. (ANDS) [hlAlert]

Rating:
Overweight
ANDS
down 40.03 %

Anadys Pharmaceuticals, Inc. (ANDS) rated Overweight by Piper Jaffray

Posted on: Tuesday,  Nov 3, 2009  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) on 11/03/2009. Previously Piper Jaffray rated Buy Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) on
02/09/2009., when the stock price was $6.17. Since then, Anadys Pharmaceuticals, Inc. has lost 40.03% as of 11/23/2011's recent price of $3.70.
If you would have followed the previous Piper Jaffray's recommendation on ANDS, you would have lost 40.03% of your investment in 1017 days.

Anadys Pharmaceuticals, Inc., is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/3/2009 8:25 AM Buy
None
1.85
as of 12/31/2009
1 Week down  -44.10 %
1 Month down  -44.10 %
3 Months down  -51.33 %
1 YTD down  -30.81 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/9/2009 8:25 AM Buy
None
6.17

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy